JAK INHIBITORS FOR ALOPECIA AREATA: 

Dr. DONOVAN'S RECENT ARTICLES 

Alopecia areata is an autoimmune disease that affects 2 % of the world.  Below you will find links to Dr. Donovan's recent articles about the use of JAK inhibitors for treating alopecia areata. 

Recent Articles on Treatment - JAK Inhibitors (Tofacitinib and Ruxolitinib, etc)

Nov 30, 2019 - Is Tofacitinib a “Cure” for Alopecia Areata?

Nov 10, 2019 - Tofacitinib and Blood Clots: What sorts of things should we be thinking about?

Nov 17, 2019 - Meta-analysis supports the use of tofacitinib in alopecia areata?

Feb 23, 2019 - High Dose Tofacitinib: What Should Patients Know?

Sept 26, 2018 - Topical JAK Inhibitors for AA: Placebo Controlled Study

May 14, 2018 - Tofacitinib for AA: How fast does regrowth occur?

Apr 13, 2018 - The Topical JAK Inhibitors for AA: Update on Progress

Jan 11, 2018 - Tofacitinib for AA: How long to use it? Can we taper?

Jan 11, 2018 - Topical Tofacitininib for Alopecia Areata: How much does it help?

Jun 27, 2017 - Topical JAK inhibitors for the eyelashes

Jun 26, 2017 - A closer look at the JAK inhibitor studies to date

Jun 25, 2017 - The Topical JAK inhibitors for Children

Jun 25, 2017 - Compounding JAK Inhibitors: How important is the pharmacist?

Jun 25, 2017 - Are lab abnormalities still possible with the topical JAKI's?

Dec 7, 2016 - Tofacitinib (Xeljanz) for Children and Teens

Nov 14, 2016 - Tofacitinib for AA in Children: How young is 'too young'?

Oct 16, 2016  - The JAK Inhibitors for AA: More Data

Apr 30, 2016 - Tofacitinib for AA: A closer look at the inflammatory markers

Mar 19, 2016 - Ruxolitinib for AA

Feb 21, 2016 - Topical ruxolitinib promotes eyebrow regrowth

Jan 11, 2016 - Nail alopecia areata helped by tofacitinib